Cancer drug combo trial pulled before it even started
NCT ID NCT06152523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a planned Phase 2 trial to test two immunotherapy drugs—monalizumab and MEDI5752—in people with metastatic cancers that have a specific genetic feature called MSI/dMMR. The study was withdrawn before enrolling any participants, so no data or results are available. The goal would have been to see if the combination could shrink tumors and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Monalizumab and MEDI5752 (a bispecific antibody targeting PD-1 and CTLA-4)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of medical oncology - Saint-Antoine Hospital
Paris, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may let cancer patients take safe breaks from immunotherapy
- Could a cancer drug spare some patients from colon surgery?
- Could immunotherapy spare some colon cancer patients from surgery?
- Live biopsy study aims to predict immunotherapy response in cancer patients
- New test could predict immunotherapy success from live tumor samples
- Cancer drug combo shows promise for Hard-to-Treat bowel cancer